Breaking AI & Tech News Analyzed

The Politicization of Science Donald Trump’s war on science has been vicious and hugely damaging, but it is worth noting that he has lost some of its biggest battles. Last year, Mr Trump demanded that US federal scientific and medical research funding be cut by about half. But the budget Congress passed in February actually delivered a slight increase in overall funding – although specific Trump targets such as the Centers for Disease Control and Prevention were cut. Resistance from Congress He also continues to chip away at science in other ways such as dismissing the board overseeing the National Science Foundation this week. Maga’s attacks on science have been nakedly political. Its defeats have been politics of a different sort, showing that the bipartisan pro-science consensus is still intact, and for the moment has the power to hold Mr Trump in check. A Global Trend What is happening in the US is not unique. Wherever rightwing populists triumph, science is likely to suffer. Jair Bolsonaro’s rule in Brazil saw him attack scientists and cut environmental funding. In India, Narendra Modi’s Hindu nationalist government purged the theory of evolution from school textbooks. In Britain, Reform UK has already attempted local government cuts, targeting net zero spending. The Changing Role of Scientists Scientists have tended to avoid party politics for a specific reason. Historians identify an implicit scientific social contract that emerged in western states after the second world war, which established the state as the main funder of research, but in theory discouraged direct political interference by government. Many scientists believe that engaging in politics endangers this compact: if scientists don’t bother politics, it won’t bother them. A New Era for Science and Politics Scientists are no longer just defending funding. They are defending the idea that science should be independent of politics. What scientists gain by organising protests, speaking to the public through their academies and now running for office is a better understanding of the changing public sphere that they are part of. The public may gain an ally against rightwing populism – and a deeper, more serious engagement with the scientific challenges facing society. Mr Trump set out to tame scientists. He may have politicised them instead.

The Lead Crystal Palace and Shakhtar Donetsk prepare to face off in the first leg of the Europa Conference League semi-final, with both teams having compelling stories to tell in this European competition. The match takes place in Krakow with kickoff scheduled for 8pm BST. The Teams' European Journeys Crystal Palace, who took 120 years to win their first major trophy, are seeking to make it "two in two" under Oliver Glasner in his final weeks at the club. They advanced to the semi-finals with a 3-0 win at home against Fiorentina in the first quarter-final leg, followed by a 2-1 loss in the second. Shakhtar Donetsk, led by former Atlético Madrid and Turkey midfielder Arda Turan, are on course for a league title in their manager's first season. The Ukrainian club is eyeing their second European trophy, having won the Uefa Cup in 2009 before the Europa League rebrand. They reached the last four with a 5-2 aggregate victory over AZ Alkmaar. The Ukrainian Club's Resilience Shakhtar's European campaign has been remarkable given the circumstances. All of their "home" Conference League matches this season have been played at the Henryk Reyman Municipal Stadium in Poland due to the ongoing conflict in Ukraine. The club has shown remarkable resilience, having lost most foreign players after special FIFA regulations allowed them to leave for free following Russia's full-scale invasion in 2022. "There is war in Ukraine and yet people live their lives," said Turan. "Every day shows that this nation never gives up." The Road to the Final The winner of this tie will face either Nottingham Forest or Aston Villa in the Europa Conference League final. Shakhtar reached the last four of the Europa League in 2016 and 2020 before the 2022 invasion changed everything for the club.

The Journey from Prototype to ClearanceBuilding a medical device is fundamentally different from standard software development. This week on Build Mode, host Isabelle Johannessen sat down with Robhy Bustami, co-founder and CEO of BioticsAI, to discuss the arduous path from a $100,000 prototype to FDA clearance. Bustami, a Startup Battlefield winner, detailed how his team is building an AI copilot for ultrasound designed to detect fetal abnormalities. The conversation revealed that the traditional startup mantra of 'move fast and break things' is obsolete in the medical sector, replaced by a necessity for extreme precision and coordination.Market Validation and Resource AllocationThe episode provides a strategic look at the 'data' driving medtech success. BioticsAI's recognition as a Startup Battlefield winner serves as a key validation of their technology's potential. However, Bustami emphasized that the primary data point for founders is not just market traction, but the successful navigation of complex regulatory pathways. This requires a significant reallocation of resources—shifting focus from rapid feature deployment to ensuring safety, reliability, and compliance with FDA standards.Shifting the MedTech CultureThe core impact of this discussion lies in the cultural shift it highlights for the industry. As timelines for FDA approval remain uncertain, the ability to maintain team morale and investor confidence becomes a critical operational metric. Bustami noted that building in a regulated industry requires a foundation of trust rather than speed. This signals a broader trend where medtech startups must balance the pressure of hyper-growth with the ethical and legal responsibilities of patient safety.The Future of AI in Healthcare RegulationLooking ahead, the medtech landscape will likely see a consolidation of companies that prioritize long-term compliance over short-term hype. As more AI copilots enter the market, the winners will be those founders who master the art of 'slow and steady' innovation. The next wave of medical breakthroughs will depend not just on algorithmic superiority, but on the ability to build sustainable organizations capable of weathering the regulatory storm.

The Challenges of FDA Approval Surviving the long road to FDA approval isn’t just about building great technology — it’s about keeping your team motivated, finding the right investors, and learning how to operate when timelines are uncertain. Lessons from BioticsAI This week on Build Mode, Isabelle Johannessen sits down with Robhy Bustami, co-founder and CEO of BioticsAI, a Startup Battlefield-winning company building an AI copilot for ultrasound to help detect fetal abnormalities. From a $100,000 prototype to FDA clearance, Bustami shares what it actually takes to build in one of the most regulated industries in the world. Building a Medtech Startup In this episode, they break down what it really looks like to build a medtech startup, including where you can’t “move fast and break things” and that every milestone takes time, coordination, and trust. Key Takeaways Team motivation is crucial during the long FDA approval process Finding the right investors is essential for medtech startups Adaptability is key when dealing with uncertain timelines Future Outlook As the medtech industry continues to evolve, startups like BioticsAI will play a critical role in shaping the future of healthcare technology. With the right approach and mindset, these companies can overcome the challenges of FDA approval and make a lasting impact.

Blockx’s Historic Run in the Spanish CapitalBelgian rising star Alexander Blockx has delivered a performance of a lifetime at the Madrid Open, defeating defending champion Casper Ruud 6-4, 6-4 to secure a spot in the semi-finals. The 21-year-old, ranked 69th, has defied all odds to reach the last four, marking his best result on clay to date.Scoreline: Blockx defeated Ruud in straight sets (6-4, 6-4).Ranking Milestone: He is the fourth lowest-ranked player to reach the men's semi-finals in Madrid.Performance: He is 4-2 against top 20 opponents this month, with all four wins coming in the last three weeks.“To be honest, I’m just happy with being here,” Blockx said. “Semi-finals is something I wouldn’t have even dreamed of to begin with.” The conditions in Madrid, characterized by slow clay and high altitude, have seemingly suited Blockx’s aggressive style, allowing him time to settle and dictate points.Ruud’s Historic Fall from GraceCasper Ruud’s loss marks a significant downturn in the Norwegian’s career trajectory. The defeat sees Ruud exit the top 20 for the first time since May 2021, signaling a potential shift in the hierarchy of men's clay-court tennis. Ruud, who had been the defending champion, struggled to find rhythm against the relentless pressure of Blockx’s game.The WTA Final and Alcaraz’s AbsenceOn the women's side, 19-year-old Mirra Andreeva battled nerves to defeat Hailey Baptiste 6-4, 7-6 (8), securing her place in the Madrid final. Andreeva, who turned 19 on Wednesday, boasts an impressive 12-1 record on clay this season. Her victory comes after a dramatic second set tie-break where she saved three set points to overcome the American.Simultaneously, the tournament was dealt a blow with the withdrawal of world No. 2 Carlos Alcaraz. The Spanish superstar is sidelined due to a right wrist injury, a setback that will prevent him from defending his French Open title in three weeks. Alcaraz was present in the stands, however, cheering on his younger brother Jaime in an under-16 tournament.Future Outlook: A New Era DawningThe Madrid Open is rapidly becoming a proving ground for the next generation of tennis talent. With Blockx and Andreeva reaching deep stages, the sport is witnessing a generational transition. For Blockx, a semi-final appearance at a Masters 1000 event is a statement of intent, suggesting he could be a major force to be reckoned with on clay in the coming years. For Ruud, the focus will shift to recovery and recalibrating his game to reclaim his position among the elite.

The Trial Continues Elon Musk's court case against Sam Altman continues on Thursday, after a day of contentious exchanges during OpenAI's cross-examination of the Tesla CEO. Musk will face another round of questioning before his lawyer calls more witnesses, including OpenAI's president, Greg Brockman. The Dispute Over OpenAI's Founding Witness testimony and evidence has revealed formerly private emails, text messages and diary entries surrounding the formation of OpenAI, giving a behind-the-scenes look at how the tech behemoth was created. Many of the tech industry's most powerful players are named as witnesses and will give their account on the origins of Musk and Altman's bitter feud. Altman is set to testify later in the trial, which will last three weeks. Musk's Allegations Against OpenAI Musk, who co-founded OpenAI in 2015, is arguing that Altman, Brockman and OpenAI broke a foundational agreement when they shifted the company from a non-profit intent on bettering humanity into a for-profit structure. Musk claims that Altman and Brockman unjustly enriched themselves and should be removed from the company. He is also seeking the undoing of the for-profit conversion and $134bn in damages to be redirected to OpenAI's non-profit arm. OpenAI's Response OpenAI rejects Musk's allegations and is attempting to show that he was always aware of plans for creating a for-profit entity. The AI firm's attorneys have stated Musk is "motivated by jealousy" of OpenAI's success after he left the company in 2018 after a failed attempt to take control. OpenAI has emphasized that it is still overseen by a non-profit. The Implications of the Trial The trial, which began on Monday with jury selection at a federal courthouse in Oakland, California, has already produced dramatic moments and bold accusations. Musk and OpenAI's lead attorney William Savitt spent most of Wednesday in a heated back and forth, with the world's richest person becoming noticeably frustrated and saying that Savitt's questions "are designed to trick me". The Future of OpenAI Silicon Valley is intently watching the trial for both its blockbuster testimony and the potential effects it will have on the AI industry. OpenAI is intending to go public later this year at around a $1tn valuation, but if Musk succeeds in this case, it could greatly complicate that effort – an outcome that would also benefit Musk's own xAI artificial intelligence firm.

Salesforce's AI Roadmap Strategy Artificial intelligence continues to advance at a dizzying clip, forcing enterprises to develop and release new products quicker than ever or risk becoming irrelevant to a faster-moving competitor. Salesforce believes it has found a strategy that allows it to keep up even if it isn’t clear where AI is headed next. The customer management software giant is crowdsourcing its AI roadmap in real time. Crowdsourcing AI Development Salesforce is certainly not the only company to work intimately with its customers for feedback on its products. However, it’s notable considering the sheer size of the company, the pace of new product launches or fixes to existing ones, and the granular level of these relationships. These aren’t annual or even quarterly discussions. Salesforce is meeting with some customers as often as once a week. The Benefits of Customer Feedback “The 18,000 customers are a wellspring of information and a wealth of information that is really needed to get to customer success,” Jayesh Govindarajan, executive vice president at Salesforce AI, told TechCrunch in a recent interview. “The stack that we’ve built has resonated with these customers. Over time we can get context to be better, and as it gets better, and LLMs get better, agent systems do more and more fully autonomous behaviors. That’s a long-running innovation track and we’re going to invest in that.” Rapid Product Releases Salesforce credits its customers for the rate of its product releases. The company told TechCrunch that by letting its customers lead the way, it is able to build an AI product roadmap that can quickly react to where AI technology is headed. Real-World Applications Engine, a travel management platform, meets with Salesforce weekly and gets access to AI tools before they’re released. PenFed, a federal credit union, developed an IT service management (ITSM) workflow on its own using existing tools and agents in Agentforce. The Future of AI Development This strategy also allows the company to roll out solutions and workflows built by users to its broader customer base too. However, it relies on the classic service sentiment that the customer is always right. Salesforce is hoping they are despite many enterprises still figuring out what role AI will play in their business, and many having yet to find value from the tech.

Manchester United's Transfer Strategy Manchester United is actively pursuing West Ham's left-back El Hadji Malick Diouf to provide competition for Luke Shaw. Diouf, a 21-year-old Senegal international, joined West Ham for €22m (£19m) from Slavia Prague and has become a crucial player for the team. Diouf's Potential and Stats Diouf's defensive skills have improved, and his crossing ability has added to his attacking threat. West Ham is aware of United's interest but may listen to offers depending on their relegation battle status. The Mainoo Contract Extension In a separate move, Kobbie Mainoo has signed a new contract with Manchester United until June 2031, earning a basic salary of about £120,000 a week. Mainoo, 21, has impressed since his first league start and is seen as a potential star by the club's director of football, Jason Wilcox. United's Midfield Priorities Manchester United is initially focusing on strengthening their midfield, with targets including Atalanta's Éderson, Newcastle's Sandro Tonali, and Nottingham Forest's Elliot Anderson. The club may also consider a left-winger or a defensive player to compete with Shaw. Financial Context West Ham's financial position, marked by losses of £104.2m for the year ending 31 May 2025, might influence their willingness to sell players this summer.

The Palantir Manifesto ControversyJust weeks after publishing a manifesto on X that implied some cultures are inferior to others, described by one UK MP as the "ramblings of a supervillain," the US spy tech company Palantir faces growing calls for a ban in Australia. The company, which has significant government contracts in Australia, now claims it is "just a software company" amid mounting public and political backlash.Cultural Statements Spark Global ConcernEarlier this month, Palantir published a manifesto on X, arguing the benefits of American power and stating: "Some cultures have produced vital advances; others remain dysfunctional and regressive." This public pronouncement, combined with concern over Palantir's software being used by ICE immigration enforcement in the United States and the Israeli military, has led to calls in Australia and the UK for governments to cease using Palantir in their operations.Financial Footprint in Australian GovernmentState and federal contracts with Palantir in Australia have reached nearly $80m, with federal investment in the company reportedly more than $160m. Federal agencies including the financial intelligence agency Austrac and the defense department have spent an estimated $60m in contracts with Palantir. Australia's sovereign wealth fund, the Future Fund, holds $100m worth of shares in the company. In Victoria, the prison system has spent nearly $20m on Palantir contracts since 2012, with a current contract valued at $9m and not due to expire until 2028.Government Response and Company DefenseAustralian Greens senator David Shoebridge has called for a "blanket ban on all new contracts with Palantir, pending a comprehensive public audit of their existing Government agreements." In response, a Palantir spokesperson emphasized that the company is "proud its software supports the Australian defense force and other government agencies" and claimed, "We don't collect or monetize data – we simply provide the tools to help customers organize and understand their own information."Regulatory Scrutiny and Future ImplicationsPalantir has identified Australia as a lucrative market for its surveillance software, achieving "protected level" in the Australian Signals Directorate's information security program. However, questions remain about compliance with the Commonwealth supplier code of conduct, which requires suppliers to avoid bringing the federal government into disrepute. With the recent termination of its lobbying relationship with Cmax Advisory and growing public concern, Palantir's future in Australia's government sector faces significant uncertainty as political pressure mounts for greater transparency and accountability.